Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

Table 3 Multivariable analysis of factors associated with presumptive/proven PJP

Model A*	OR (95% CI)	P
AIDS	3.31 (1.13–9.64)	0.029^§
Non-Hodgkin Lymphoma	3.71 (1.23–11.18)	0.020^§
Vasculitis	5.95 (1.07–33.22)	0.042^§
Metastatic solid tumor	4.31 (1.76–10.53)	0.001^§
Invasive mechanical ventilation	0.43 (0.24–0.80)	0.007^§
Blood lymphocyte count in cells × 10^–3/mm³	0.64 (0.42–1.00)	0.049^§
Serum CRP in mg/L	1.00 (1.00–1.01)	0.061
Bilateral ground glass	2.19 (1.01–4.78)	0.048^§

Model B**	OR (95% CI)	P
AIDS	4.06 (1.24–13.28)	0.021^§
Non-Hodgkin Lymphoma	3.42 (0.85–13.80)	0.084
Vasculitis	6.34 (1.09–36.76)	0.039^§
Metastatic solid tumor	7.05 (2.45–20.31)	< 0.001^§
Invasive mechanical ventilation	0.61 (0.29–1.28)	0.192
Blood lymphocyte count in cells × 10^–3/mm³	0.442 (0.17–1.18)	0.102
Serum CRP in mg/L	1.16 (0.74–1.81)	0.512
Bilateral ground glass	2.89 (1.14–7.32)	0.025^§

AIDS, acquired immune deficiency syndrome; CI, confidence interval; CRP, C-reactive protein; OR, odds ratio; PJP, Pneumocystis jirovecii pneumonia
*Only variable retained in the final multivariable model are presented in the table
**Generalized linear mixed model (GLMM) with center as random effect. Convergence of the mixed model was obtained after standardization of continuous variables and using the “bobyqa” optimizer. The model was built using the glmer function in the lme4 package for R Statistical Software (version 3.6.0, R Foundation for Statistical Computing, Vienna, Austria)
^§P < 0.05

ISSN: 1364-8535